Laura Stanbery

1.7k total citations · 1 hit paper
54 papers, 1.1k citations indexed

About

Laura Stanbery is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Laura Stanbery has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 16 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in Laura Stanbery's work include Cancer Immunotherapy and Biomarkers (16 papers), PARP inhibition in cancer therapy (12 papers) and Immunotherapy and Immune Responses (11 papers). Laura Stanbery is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), PARP inhibition in cancer therapy (12 papers) and Immunotherapy and Immune Responses (11 papers). Laura Stanbery collaborates with scholars based in United States and United Kingdom. Laura Stanbery's co-authors include John Nemunaitis, Susan Morand, Monika Devanaboyina, Lance D. Dworkin, Gerald M. Edelman, Danae Hamouda, Khalil Choucair, Justin F. Creeden, Daniel J. Craig and Luisa Manning and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Laura Stanbery

51 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ovarian Cancer Immunotherapy and Personalized Medicine

2021 236 citations Susan Morand, Monika Devanaboyina et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Stanbery United States	17	557	441	273	242	198	54	1.1k
Julia V. Burnier Canada	21	408 0.7×	592 1.3×	174 0.6×	318 1.3×	123 0.6×	73	1.2k
Sachi Horibata United States	16	477 0.9×	838 1.9×	550 2.0×	281 1.2×	123 0.6×	31	1.6k
Ashwini A. Katre United States	16	685 1.2×	802 1.8×	135 0.5×	350 1.4×	106 0.5×	31	1.3k
Marsela Braunstein Canada	11	450 0.8×	638 1.4×	320 1.2×	374 1.5×	137 0.7×	15	1.4k
Hong Zheng China	13	569 1.0×	632 1.4×	505 1.8×	179 0.7×	118 0.6×	67	1.4k
Stéphanie Lheureux Canada	15	735 1.3×	331 0.8×	161 0.6×	135 0.6×	116 0.6×	46	991
Isabelle Matte Canada	20	424 0.8×	514 1.2×	403 1.5×	200 0.8×	85 0.4×	22	1.2k
Sofia Genta Canada	12	434 0.8×	289 0.7×	170 0.6×	135 0.6×	139 0.7×	36	742
Denarda Dangaj Laniti Switzerland	15	703 1.3×	367 0.8×	544 2.0×	186 0.8×	78 0.4×	31	1.1k
Elizabeth Ruth Plummer United Kingdom	19	961 1.7×	836 1.9×	137 0.5×	181 0.7×	116 0.6×	69	1.3k

Countries citing papers authored by Laura Stanbery

Since Specialization

Citations

This map shows the geographic impact of Laura Stanbery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Stanbery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Stanbery more than expected).

Fields of papers citing papers by Laura Stanbery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Stanbery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Stanbery. The network helps show where Laura Stanbery may publish in the future.

Co-authorship network of co-authors of Laura Stanbery

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Stanbery. A scholar is included among the top collaborators of Laura Stanbery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Stanbery. Laura Stanbery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morand, Susan, et al.. (2025). Clinical characterization and therapeutic targeting of fusion genes in oncology. Future Oncology. 21(10). 1249–1260.

Morand, Susan, Rachel Royfman, Aditi Singh, et al.. (2024). Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer. International Journal of Molecular Sciences. 25(6). 3173–3173. 3 indexed citations

Nemunaitis, John, et al.. (2023). Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer. Oncology Reviews. 17. 11471–11471. 4 indexed citations

Anderson, Peter M., Brian D. Crompton, Kelly Klega, et al.. (2023). Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research. 29(9). 1689–1697. 15 indexed citations

Moon, Seongjun, Do Hoon Kim, Xiuquan Luo, et al.. (2023). A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells. Advanced NanoBiomed Research. 3(8). 2 indexed citations

Nemunaitis, John, Laura Stanbery, David Willoughby, et al.. (2023). Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response. Cancers. 15(23). 5616–5616. 4 indexed citations

Moon, Seongjun, Do Hoon Kim, Xiuquan Luo, et al.. (2023). A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells. SHILAP Revista de lepidopterología. 3(8). 1 indexed citations

Stanbery, Laura, et al.. (2022). Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. Current Problems in Cancer. 47(1). 100917–100917. 56 indexed citations

Rocconi, Rodney P., Laura Stanbery, Min Tang, et al.. (2022). ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. SHILAP Revista de lepidopterología. 2(1). 106–106. 8 indexed citations

10.

Barve, Minal, Phylicia Aaron, Luisa Manning, et al.. (2022). Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights Oncology. 16. 1363231461–1363231461. 15 indexed citations

11.

Royfman, Rachel, et al.. (2021). Adenomatous polyposis coli in cancer and therapeutic implications. Oncology Reviews. 15(1). 534–534. 25 indexed citations

12.

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 161(3). 676–680. 26 indexed citations

13.

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 163(3). 459–464. 14 indexed citations

14.

Devanaboyina, Monika, et al.. (2021). GM-CSF: Anti-Cancer Immune Response and Therapeutic Application. Journal of Vaccines & Vaccination. 2–13. 1 indexed citations

15.

Adams, Ned, Laura Stanbery, Luisa Manning, et al.. (2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 9(10). 1201–1201. 6 indexed citations

16.

Morand, Susan, Khalil Choucair, David Willoughby, et al.. (2021). Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. Cancer Gene Therapy. 29(7). 993–1000. 5 indexed citations

17.

Cassidy, Christine, et al.. (2020). FDA efficiency for approval process of COVID-19 therapeutics. Infectious Agents and Cancer. 15(1). 73–73. 10 indexed citations

18.

Morand, Susan, Rachel Royfman, Monika Devanaboyina, et al.. (2020). Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer. 12(1). 38–53. 47 indexed citations

19.

Stanbery, Laura, et al.. (2019). HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report. Gynecologic Oncology Reports. 31. 100520–100520. 9 indexed citations

20.

Peterson, Esther A., et al.. (2011). SEPT9_i1 and genomic instability: Mechanistic insights and relevance to tumorigenesis. Genes Chromosomes and Cancer. 50(11). 940–949. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact